Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 4,060,000 shares, a growth of 10.9% from the July 31st total of 3,660,000 shares. Currently, 20.2% of the company’s shares are sold short. Based on an average daily volume of 271,200 shares, the days-to-cover ratio is currently 15.0 days.

Dianthus Therapeutics Stock Performance

DNTH traded down $1.18 during trading on Tuesday, hitting $27.65. The stock had a trading volume of 139,519 shares, compared to its average volume of 189,833. The stock has a 50 day simple moving average of $27.79 and a two-hundred day simple moving average of $25.89. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77. The company has a market capitalization of $811.53 million, a PE ratio of -4.74 and a beta of 1.89.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The business had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million. On average, equities research analysts anticipate that Dianthus Therapeutics will post -2.32 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on DNTH. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, August 12th. Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Wedbush reduced their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Cantor Fitzgerald initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating on the stock. Finally, Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $44.71.

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bain Capital Life Sciences Investors LLC acquired a new stake in shares of Dianthus Therapeutics during the first quarter worth about $89,761,000. RA Capital Management L.P. acquired a new stake in Dianthus Therapeutics during the 1st quarter valued at approximately $69,990,000. Vanguard Group Inc. boosted its holdings in shares of Dianthus Therapeutics by 250.0% in the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after acquiring an additional 384,182 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth $11,251,000. Finally, Vestal Point Capital LP purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth $1,404,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.